Clinical trials open for the enrollment
Title: MK-7902-014/E7080-G000-320/LEAP-014: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080-MK-7902) Plus Chemotherapy In Participants With Metastatic Esophageal Carcinoma
Based on the hypothesis that the combination of lenvatinib (tyrosine kinase inhibitor) and pembrolizumab (anti-PD-1) is superior to pembrolizumab alone, this study offers the possibility of associating this combination with standard chemotherapy (fluoropyrimidines and platinum or taxanes and platinum based schemes), comparing it with pembrolizumab in combination with chemotherapy
For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Title: innovaTV207 – “Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors”
In this trial are investigated efficacy and safety of tisotumab vedotin, antbody- drugconjugate direct against tissutal factor, alone or in association with other drugs, in following neoplasms: colorectal, non-small cell lung cancer, exocrine pancrea, head and neck.
Principal Investigator: Prof. Pierfrancesco Tassone
For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Title: CA043-001 – An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Phase 1/2 first-in-human trial that investigates role of BMS-986288 (a modified form of ipilimumab), alone or in association to nivolumab, in various tumors.
Principal Investigator: Prof. Pierfrancesco Tassone
ENROLLMENT ACTUALLY NOT ACTIVE
Clinical trials closed for the enrollment
Title: DS8201-A-U306 – “A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: MK7902-015 – “Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: ROME – “The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: DZB-CS-202 – “A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)”
Principal Investigator: Prof. Pierfrancesco Tassone